Deutsches Institut für Bautechnik

2022 Techtextil Innovation Award Winners Reflect Growing Pressure to Achieve Circularity - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Textiles, Manufacturing, HMF, Printing, Intelligence, Pressure, Dresden University of Technology, Deutsches Institut für Bautechnik, Institute of technology, ITM, Tanning, Biomass, Textile, Cellulose, Editorial, Clothing, Renewable energy, Wool

The "Editorial: 2022 Techtextil Innovation Award Winners Reflect Growing Pressure to Achieve Circularity" report from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Editorial: 2022 Techtextil Innovation Award Winners Reflect Growing Pressure to Achieve Circularity" report from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering.
  • There was a heavy emphasis on sustainability at the 2022 edition of Techtextil, held in Frankfurt, Germany, during June 2022 - and this was reflected in the innovations presented by the nine winners of the 2022 Techtextil Innovation Awards.
  • At the same time, the winners proposed new uses to which technical textiles can be put in order to solve a variety of societal challenges.
  • FibreCoat presented a new aluminium coated basalt fibre, and Kelheim Fibres and Sachsisches Textilforschungsinstitut (STFI - Saxon Textile Research Institute) presented a reusable cloth diaper made entirely of sustainable materials.

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Surgery, Medical Devices, Health, Physical Therapy, Opus, Insurance, Drug Quality and Security Act, Communication, SEC, Risk, Legacy, Science, Gaps, Organization, Annual report, NASDAQ, Biologic, Cell, Patient, Hospital, Deutsches Institut für Bautechnik, Injury, Pelvis, Multimedia, Securities Act of 1933, Partnership, Technology, Spine, Ministry of Education (Malaysia), Company, Trinity, International Institute for Applied Systems Analysis, Advanced Therapy Medicinal Product, Opus One, German Institute for Medical Documentation and Information, Securities Exchange Act of 1934, DBM, Extremities, Terminology, MTF, Surgeon, Medical device, Dentistry, Pharmaceutical industry

Legacy DBM is processed by MTF Biologics, leveraging decades of experience through tailored processing methods that preserve the inherent growth factors natural to the bone.

Key Points: 
  • Legacy DBM is processed by MTF Biologics, leveraging decades of experience through tailored processing methods that preserve the inherent growth factors natural to the bone.
  • View the full release here: https://www.businesswire.com/news/home/20221013005058/en/
    Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects.
  • Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.
  • This comprehensive portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.

Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Retrieved on: 
Wednesday, October 12, 2022
Biotechnology, Physical Therapy, Publishing, Surgery, General Health, Health, Medical Devices, Communications, Insurance, Elective surgery, Drug Quality and Security Act, Communication, Risk, SEC, Technology, Efficiency, Science, Organization, Â, NASDAQ, Annual report, Cell, Patient, Hospital, Carbon, Deutsches Institut für Bautechnik, NASS, Multimedia, Securities Act of 1933, Temperature, North American Spine Society, Publication, Company, International Institute of Refrigeration, Advanced Therapy Medicinal Product, German Institute for Medical Documentation and Information, Securities Exchange Act of 1934, Overalls, Dry ice, Terminology, MTF, Surgeon, Bookbinding, Pharmaceutical industry, Dentistry, Medical device, Orthopedic surgery, Spine, Virtuos

View the full release here: https://www.businesswire.com/news/home/20221012005256/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005256/en/
    Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute for use with spine and orthopedic procedures (Photo: Business Wire)
    The Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute prepared by MTF Biologics through a proprietary process that preserves the biological components necessary for bone healing.
  • Additionally, Virtuos offers significant logistical and cost-saving advantages to the hospital with improved shipping, storage and operating room efficiency.
  • We are pleased to present Orthofix and MTF Biologics with the Best Technology in Spine award for the Virtuos Lyograft.
  • On behalf of our partner MTF Biologics and the team of dedicated employees at Orthofix, we are honored to receive this award, said Orthofix President of Global Spine Kevin Kenny.

Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Retrieved on: 
Tuesday, July 26, 2022
Biotechnology, Neurology, Surgery, Medical Devices, Health, Dry ice, Surgeon, Carbon, Insurance, Hospital, Deutsches Institut für Bautechnik, Advanced Therapy Medicinal Product, SEC, Temperature, Risk, Partnership, Hand, Securities Act of 1933, Securities Exchange Act of 1934, International Institute of Refrigeration, Multimedia, NASDAQ, Trinity, Ministry of Education (Malaysia), German Institute for Medical Documentation and Information, Organization, Cell, Spine, Technology, Company, Biologic, MTF, Science, Patient, Efficiency, Baylor Scott & White Medical Center – Temple, Overalls, Terminology, Annual report, Elective surgery, Drug Quality and Security Act, Communication, Medical device, Pharmaceutical industry, Virtuos

(NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the limited market release and first patient implant of the Virtuos Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopedic procedures.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the limited market release and first patient implant of the Virtuos Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopedic procedures.
  • View the full release here: https://www.businesswire.com/news/home/20220726005177/en/
    Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopedic procedures in a room-temperature, ready-to-use, moldable form.
  • This helps ensure we can always have an easy-to-use, moldable, complete bone graft on hand, and it streamlines the preparation and overall surgical procedure time.
  • The Virtuos Lyograft provided through our exclusive partnership with MTF Biologics is at the forefront of allograft technology, said Orthofix President of Global Spine Kevin Kenny.

Orthofix and MTF Biologics Expand Partnership Agreement

Retrieved on: 
Tuesday, May 3, 2022
Science, Other Philanthropy, Other Science, Research, Health, Medical Devices, Philanthropy, Other Health, Opus, International Institute for Applied Systems Analysis, Elective surgery, Communication, German Institute for Medical Documentation and Information, Osteon, Insurance, The Legacy, NASDAQ, Company, Securities Exchange Act of 1934, Cell, Legacy, Securities Act of 1933, Party, Patient, Partnership, Risk, Organization, Bone, MTF, Annual report, Drug Quality and Security Act, Hospital, DBM, Spine, Trinity, Science, Surgeon, Deutsches Institut für Bautechnik, Advanced Therapy Medicinal Product, SEC, Solution, Technology, Terminology, CEO, Multimedia, Pharmaceutical industry, Ceramic, Medical device

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts, said Orthofix President of Global Spine Kevin Kenny.
  • This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings.
  • MTF Biologics is pleased to strengthen our exclusive partnership with Orthofix to continue our joint investments in innovative solutions, and the provision of Trinity Elite and Trinity Evolution allografts, said Joe Yaccarino, President and CEO MTF Biologics.
  • The Legacy DBM will be a complementary addition to the Orthofix demineralized bone line which consists of FiberFuse Advanced and FiberFuse Strip, both also provided by MTF Biologics.

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

Retrieved on: 
Monday, March 7, 2022
Medical Supplies, Medical Devices, Health, Research, Science, Biotechnology, Private Securities Litigation Reform Act, Trauma, Patient, Regenerative medicine, Hospital, Science, Research, Financial condition report, Deutsches Institut für Bautechnik, Spinal fusion, DBM, Conversation, Advanced Therapy Medicinal Product, Security (finance), Organization, U.S. Securities and Exchange Commission, Federal Food, Drug, and Cosmetic Act, Growth, Company, Form, Cell, International Institute for Nanotechnology, MTF, Osteon, Risk, Analysis, Technology, Spine, Result, Publication, Bharat Immunologicals and Biologicals Corporation, German Institute for Economic Research, Osteoporosis, NASDAQ, Pharmaceutical industry

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM).

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM).
  • MTF Biologics is a global nonprofit organization that provides one of the orthopedic industrys largest portfolios of allograft tissue.
  • Bone Biologics is developing a bone graft substitute product consisting of rhNELL-1 and a carrier, to be supplied by MTF Biologics, for the initiation and improvement of bone formation.
  • MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science.

MTF Biologics Awards More Than $1 Million in 2021 Research Grants to Support Allograft Research

Retrieved on: 
Wednesday, February 9, 2022
Health, Other Health, Other Science, General Health, Research, Science, German Institute for Economic Research, The Foundation for Young Australians, Injury, Intention, Intellectual property, Deutsches Institut für Bautechnik, Oregon Health & Science University, School of Biological Sciences, University of Manchester, Orthopaedic Research Society, Request for proposal, RESEARCH, Cell, Program, Science, Proposal, Clinician Administered PTSD Scale, Research, Composite, EVP, Patient, Technology, Hospital, Sirindhorn International Institute of Technology, CEO, Organization, MTF, Decellularization, Advanced Therapy Medicinal Product, Doctor of Philosophy, Machine learning, Transplant, Request, Pharmaceutical industry, Dentistry, Medicine

MTF Biologics Extramural Research Grants Program has fueled promising research for more than three decades, said Joe Yaccarino, President and CEO of MTF Biologics.

Key Points: 
  • MTF Biologics Extramural Research Grants Program has fueled promising research for more than three decades, said Joe Yaccarino, President and CEO of MTF Biologics.
  • MTF Biologics continues to create opportunities to advance science and heal lives through support of pioneering allograft research, added Marc Long, Ph.D., EVP, Research & Development of MTF Biologics.
  • We continue to be impressed by the quality of the grant proposals we receive, said Jeffrey Cartmell, Ph.D., Director, Intellectual Property & Grants at MTF Biologics.
  • 2021 MTF Biologics Research Grant Award recipients include:
    MTF BIOLOGICS EXTRAMURAL RESEARCH GRANT ESTABLISHED INVESTIGATOR:
    MTF BIOLOGICS EXTRAMURAL RESEARCH GRANT JUNIOR INVESTIGATOR:
    Karina Nakayama, Ph.D., Oregon Health & Science University, Repair of Composite Muscle-bone Injury Using Decellularized Muscle Allografts and Rehabilitative Exercise
    ORTHOPAEDIC RESEARCH & EDUCATION FOUNDATION MTF BIOLOGICS CAREER DEVELOPMENT GRANT: (Administered by the Orthopaedic Research and Education Foundation)
    ORTHOPAEDIC RESEARCH & EDUCATION FOUNDATION - HERNDON RESIDENCY AWARD: (Administered by the Orthopaedic Research and Education Foundation)
    Letters of Intent are now being accepted for the 2022 MTF Biologics Extramural Grant Program.

MTF Biologics Appoints George Herrera Executive Vice President of Donor Services

Retrieved on: 
Monday, October 4, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Medical Devices, Research, Surgery, Science, Clinical Trials, Transplant, National Kidney Foundation, American Association, Business administration, Public sector banks in India, Multimedia, Patient, United Nations University International Institute for Software Technology, Association, Deutsches Institut für Bautechnik, Master of Business Administration, Development, Hospital, Board, Advanced Therapy Medicinal Product, University, Herrera, American Association of Tissue Banks, Technology, Cell, AATB, Tulane University, German Institute for Economic Research, Organization, MTF, EVP, Pharmaceutical industry, Management, Dentistry

MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science, today announced it has named George Herrera Executive Vice President, Donor Services.

Key Points: 
  • MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science, today announced it has named George Herrera Executive Vice President, Donor Services.
  • View the full release here: https://www.businesswire.com/news/home/20211004005704/en/
    George Herrera, Executive Vice President of Donor Services (Photo: Business Wire)
    In his new role, Herrera will oversee all public awareness initiatives related to tissue donation and provide strategic leadership and management to multiple MTF Biologics Divisions: Donor Services , International Institute for the Advancement of Medicine (IIAM) and Statline .
  • The Donor Services Division works to increase tissue donation and provides services to honor donor families and the gift of donation.
  • Herrera joined MTF Biologics in 1997 as a Regional Director of Donor Services and most recently served as Vice President, Donor Services.